Wire · opportunities
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The FDA approved daraxonrasib, a first-in-class targeted oral therapy for metastatic pancreatic adenocarcinoma, based on phase III trial data showing a near doubling of median overall survival in treated patients. The drug received Breakthrough Therapy, Orphan Drug designations, and Priority Review, highlighting accelerated regulatory pathways for serious oncology treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 51 sources have reported it between 26 Aug 2026 and 10 Sep 2026.
◆ ◆ The Wire takeaway
The FDA’s early approval signals faster regulatory routes for novel cancer treatments. If you are building targeted oncology drugs, now’s the time to engage FDA programs to speed your path to market.
◆ Coverage
51 sources · first reported 26 Aug 2026 · latest 10 Sep 2026
◆ Related on Wire
◆ Topics